FDA authorizes alternative dosing regimen for monkeypox vaccine - increasing doses available for use in adults by up to 5-fold without compromising quality or safety
The U..S Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) allowing healthcare providers to use an alternative dosing regimen of the JYNNEOS vaccine for individuals 18 years of age and older determined to be at high risk of monkeypox infection. This will increase the total number of doses available for use by up to five-fold.